Flexible Electronics News

Canatu Grants License for Production of CNT Pellicle Membranes

The license authorizes FST as the licensee to mass-produce CNT pellicle membranes using the CNT100 SEMI reactor.

Source: Canatu

Canatu Plc announces that it has granted a commercial production license for the first CNT100 SEMI reactor to Korean semiconductor company Fine Semitech Corporation (FST)to mass-produce CNT pellicle membranes.  

The license authorizes FST as the licensee to mass-produce CNT pellicle membranes using the CNT100 SEMI reactor, which will be operated by FST. FST will pay Canatu a one-time license fee for the commercial production rights.

The commencement of commercial production will also create two new sources of future revenue streams for Canatu:

• Sales of proprietary consumables used in the CNT manufacturing process by Canatu.

• Royalties payable to Canatu on each CNT pellicle sold by FST to its end customers.

“This marks a significant milestone, bringing our customer closer to high-volume mass production of CNT pellicle membranes. It also validates the maturity of CNT pellicle technology and demonstrates market demand for CNT pellicles,” says Juha Kokkonen, CEO of Canatu.

The first CNT100 SEMI reactor was shipped to FST in September 2024. In July 2025, Canatu announced that the reactor and associated post-processing equipment had passed the customer approval.

Keep Up With Our Content. Subscribe To Ink World magazine Newsletters